ARCHIVES

Randomized Trials Discovered Roles For Newly Approved Nexavar and Sutent.

This article is from The Cancer Letter archive.

Vol. 32 No. 07 | February 24, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Director Challenges Scientists To Develop Molecular “Fingerprints” Of Tumors

December 4, 1998

Advisors seek support for NCI’s “special authorities” granted in 1971.

July 15, 2005

In Brief: NCI Recieves Two Proposals For Antineoplaston Trials, None For Children; Stubble Elected To NAS

June 19, 1992

NCI To Get $1.469 billion In FY88 Appropriations Bill, An Increase Of $67 Million Over FY 1987

January 1, 1988

Controversy Continues, Scientists, Advocates, Clinicians Say

January 31, 1997

Large Studies Show Promising Results For Targeted Therapies Alimta, Tarceva

June 26, 2009